Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Operating Leases (2019 - 2025)

Regenxbio has reported Operating Leases over the past 7 years, most recently at $65.2 million for Q4 2025.

  • Quarterly results put Operating Leases at $65.2 million for Q4 2025, down 12.03% from a year ago — trailing twelve months through Dec 2025 was $65.2 million (down 12.03% YoY), and the annual figure for FY2025 was $65.2 million, down 12.03%.
  • Operating Leases for Q4 2025 was $65.2 million at Regenxbio, down from $67.4 million in the prior quarter.
  • Over the last five years, Operating Leases for RGNX hit a ceiling of $88.8 million in Q4 2022 and a floor of $65.2 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $82.3 million (2021), compared with a mean of $79.6 million.
  • Biggest five-year swings in Operating Leases: soared 1062.78% in 2021 and later decreased 12.03% in 2025.
  • Regenxbio's Operating Leases stood at $84.9 million in 2021, then increased by 4.56% to $88.8 million in 2022, then dropped by 7.41% to $82.2 million in 2023, then dropped by 9.84% to $74.1 million in 2024, then fell by 12.03% to $65.2 million in 2025.
  • The last three reported values for Operating Leases were $65.2 million (Q4 2025), $67.4 million (Q3 2025), and $69.6 million (Q2 2025) per Business Quant data.